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Abstract
Background: Neonatal Opiate Withdrawal Syndrome (NOWS) has been a concern in the
United States, with an incidence of 20 cases per 1000 live births. Most research on NOWS
uses length of stay (LOS) in the hospital or length of pharmacological treatment (LOT) as
outcome measures for treatment effectiveness. However, LOS does not account for other
factors impacting neonatal care, such as other medical or social confounders. LOT may be a
more precise measure to evaluate treatment effectiveness but does not account for possible
need to continue close, in-hospital monitoring of withdrawal symptoms. Therefore, the aim
of our research is to evaluate LOT and LOS, assessing what factors prolong hospital stay
after completing pharmacological treatment for NOWS.
Objective: To evaluate factors that contribute to the difference between LOT and LOS.
Methods: A retrospective medical chart review of all neonates born to mothers with
evidence of substance use/abuse from 2011 – 2017 at a tertiary care center was conducted
by using EPIC EHR system. Neonates over 35 weeks gestational age with in-utero opioid
exposure and no other major congenital anomalies, who received pharmacological
treatment for NOWS were included. Demographic data as well as outcome data related to
the difference between LOT and LOS was analyzed using multivariate analysis. Prolonged
hospital stay is considered for LOS-LOT greater than 48 hours.
Results: 229 neonates were included in the study with median LOT 22 days and median
LOS 29 days. Of the 62% who had prolonged hospital stay after cessation of
pharmacological treatment for NOWS, 43% were due to a hold placed by child protection
service. There was a correlation in increased time between LOT and LOS and maternal age
(p=0.001), as well as receiving treatment in the NICU (p=0.005). There is a trend towards a
shorter stay in neonates with higher birth weight (p=0.05) and gestational age (p=0.08).
Maternal polysubstance use did not statistically increase the stay (p=0.929). Prolonged stay
had no effect on readmission within 30 days (p=0.882). Mean LOS and LOT per year of
birth were statistically different (p<0.001), while mean LOS-LOT per year of birth was not
(p=0.114).
Conclusions: Close to half of the babies treated for NOWS had a pronged LOS, most of
which was due to a social hold or a hold by child protective services. The average cost of
treatment for infants with NOWS is $79,937.75. By addressing underlying factors that
prolong the stay in the hospital past medical care, we may be able to decrease medical
spending and improve overall care for these neonates.

Introduction
NOWS includes a constellation of
symptoms in neonates following in utero
exposure to maternal opioids. The
incidence of NOWS has risen over the
past 20 years and is accompanied by a
high cost of care. Depending on
symptom severity, NOWs is treated with
either nonpharmacological interventions
or various opioids, with possible adjunct
medications. Most research on NOWS,
including studies assessing treatment
pharmacotherapy and hospital service,
use length of stay (LOS) as primary
outcome measure for treatment
effectiveness. However, the utility of this
measure, how it corresponds to treatment
efficacy and to length of treatment
(LOT), is uncertain.

Objective
To determine what factors effect length of treatment (LOT), and the difference
between LOT and length of hospital stay (LOS) in neonates with NOWS.

Demographics
Mean Maternal Age, years

29.3

Male, n (%)

128 (55.9%)

C-section, n (%)

94 (26.8%)

Mean Birth weight, grams

2975

Mean Gestational Age, weeks

37.4

Readmissions, n (%)

18 (7.9%)

Treated with Phenobarbital, n (%)

98 (42.8%)

Mean Length of Treatment, days
Mean Length of Hospital Stay, days
Prolonged stay, n (%)
Mean difference LOT-LOT, days

25.6
32.4
143 (62.4%)
6.1

Reasons for
Prolonged Stay
Child Protection
Placed Hold

61 (41.7%)

NAS Scoring
Continued
(Borderline Scores)

23 (16.1%)

Other Medical
Conditions

Figure 1. Mean LOS, LOT, and difference between
LOS and LOT by year of birth
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Results

Time Unreasonable 38 (26.6%)
for Discharge
Monitoring Feeding

•
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Methods
Retrospective medical record review conducted by using EPIC EHR system
Neonates diagnosed and pharmacologically treated for NOWS from 2011 – 2017
3 scores ≥ 8 on the Modified Finnegan Neonatal Abstinence Scoring Tool (FNAST)
was considered indicative of withdrawal that required pharmacological treatment
Prolonged LOS > 48 hours following cessation of pharmacological treatment for
NOWS; reason for prolonged stay determined
The difference between LOS and LOT was assessed for correlation with demographic
data and treatment factors using Ordinary Least Squares regression and the MannWhitney U Test

6 (4.2%)
15 (10.5%)

•
•
•
•
•
•
•
•

A total of 229 neonates were identified
The median LOT was 22 days and the median LOS was 29 days
62% of included neonates had a prolonged stay
43% of the prolonged stays were attributable to a hold placed by child protection
service
Increased time between LOT and LOS correlated with increased maternal age
(p=0.001) and treatment received in the NICU (p=0.005)
Trend between shorter stay and higher birth weight (p=0.05) and gestational age
(p=0.08)
No relationship between polysubstance use (p=0.929) or readmission within 30 days
(p=0.882) and prolonged stay.
Mean LOS and LOT per year of birth were statistically different (p<0.001), but the
difference between LOS and LOT was not impacted by time (p=0.114) (Figure 1).

Conclusions
Over half the neonates pharmacologically treated for NOWS had a prolonged stay after
cessation of treatment, over 40% of this was due to a hold placed by child protective
services. LOS and LOT were impacted by a variety of factors, including year of birth.
More research is needed to assess methods of decreasing prolonged LOS after
termination of treatment, which can lead to decreased healthcare burden.
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2.
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